Matti Poutanen profile picture
Matti
Poutanen
Professor, Institute of Biomedicine
PhD

Contact

+358 29 450 2632
+358 50 366 0140
Kiinamyllynkatu 10
20520
Turku

Areas of expertise

gentically modified mice
sex steroids
endometriosis
hormonal cancer

Biography

EDUCATIONAL TRAINING

1987, M.Sc., Department of Biochemistry, University of Oulu, Finland

1993, Ph.D., Department of Clinical Chemistry, University of Oulu, Finland         

1997, Title of Docent (Adjunct professor); Biochemical Endocrinology, University of Oulu, Finland   


CURRENT POSITIONS

Professor, Department of Physiology, University of Turku, and Director of Turku Center for Disease Modeling, University of Turku, Finland

Senior Scientist lecturer, Institute of Medicine, The Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

MAJOR GRANTS:
Academy of Finland, The Finnish Cancer Organisations, Sigrid Juselius Foundation, Novo Foundation, Vetenskaps Rådet, Business Finland and Industry

SUPERVISION OF STUDENTS: 30 PhD students supervised, 6 in training.

SCIENTIFIC AND SOCIETAL IMPACT OFD THE WORK

Research is mainly focused on sex steroid synthesis and action, with total number of citation 6270 (Web of Science, April 2018); number of citations in 2017: ~400; average citations per article: 26.8; h-index: 46; 182 original peer-reviewed publications; 5 publications in high-impact journals (I.F. ≥ 10): J. Clin. Invest. 2x (I.F. 13), Cell Metab.(I.F. 17), Nat. Med. (I.F. 28), Gut (I.F. 14)

 Co-founder, Forendo Pharma ltd (www.forendo.com) focusing on hormonal therapies for endometriosis and male hypogonadism. The company has closed its investment rounds with the leading Nordic start-up investors Karolinska Development AB, Novo Seeds and Finnvera. 

Teaching

Teaching experience in, endocrinology, developmental biology, hormonal cancer, GM mice and animal models and in vivo imaging

Research

Our research group has been internationally in a key position in providing evidence for the concept where the ligand concentration available for steroid hormone receptor binding is markedly regulated by the target tissue metabolism, termed intracrine steroid hormone action. The concept has proven to be essential for the growth and progression of both prostate and breast cancer. We, furthermore, have shown this concept to be valid also in premenopausal women, eg. in the endometriosis, and other medically relevant implications are expected to rise in the near future.

Publications

Sort by: